The stock of CureVac N.V (CVAC) has gone up by 26.88% for the week, with a 66.68% rise in the past month and a 86.76% rise in the past quarter. The volatility ratio for the week is 3.10%, and the volatility levels for the past 30 days are 4.98% for CVAC. The simple moving average for the past 20 days is 30.91% for CVAC’s stock, with a 72.23% simple moving average for the past 200 days.
Is It Worth Investing in CureVac N.V (NASDAQ: CVAC) Right Now?
The price-to-earnings ratio for CureVac N.V (NASDAQ: CVAC) is above average at 6.28x, Company’s 36-month beta value is 2.49.Analysts have differing opinions on the stock, with 2 analysts rating it as a “buy,” 1 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for CVAC is 93.99M, and currently, short sellers hold a 4.47% ratio of that floaft. The average trading volume of CVAC on June 12, 2025 was 652.55K shares.
CVAC) stock’s latest price update
CureVac N.V (NASDAQ: CVAC) has experienced a rise in its stock price by 39.04 compared to its previous closing price of 4.07. However, the company has seen a gain of 26.88% in its stock price over the last five trading days. schaeffersresearch.com reported 2025-06-12 that Biotech stock CureVac NV (NASDAQ:CVAC) was last seen up 32.2% at $5.37, after news that BioNTech (BNTX) is acquiring the company in all-stock deal worth $1.25 billion.
Analysts’ Opinion of CVAC
Many brokerage firms have already submitted their reports for CVAC stocks, with Leerink Partners repeating the rating for CVAC by listing it as a “Market Perform.” The predicted price for CVAC in the upcoming period, according to Leerink Partners is $4 based on the research report published on April 25, 2024 of the previous year 2024.
SVB Securities, on the other hand, stated in their research note that they expect to see CVAC reach a price target of $13. The rating they have provided for CVAC stocks is “Outperform” according to the report published on June 08th, 2023.
UBS gave a rating of “Buy” to CVAC, setting the target price at $18 in the report published on January 19th of the previous year.
CVAC Trading at 54.38% from the 50-Day Moving Average
After a stumble in the market that brought CVAC to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 13.18% of gains for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CVAC starting from Thaminda Ramanayake, who proposed sale 6,986 shares at the price of $3.34 back on May 07 ’25. After this action, Thaminda Ramanayake now owns shares of CureVac N.V, valued at $23,316 using the latest closing price.
Myriam Mendila, the affiliate of CureVac N.V, proposed sale 17,839 shares at $4.93 during a trade that took place back on Jan 07 ’25, which means that Myriam Mendila is holding shares at $88,019 based on the most recent closing price.
Stock Fundamentals for CVAC
Current profitability levels for the company are sitting at:
- 0.33 for the present operating margin
- 0.8 for the gross margin
The net margin for CureVac N.V stands at 0.3. The total capital return value is set at 0.24. Equity return is now at value 34.46, with 26.30 for asset returns.
Based on CureVac N.V (CVAC), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at 2.61.
Currently, EBITDA for the company is 209.69 million with net debt to EBITDA at -2.19. When we switch over and look at the enterprise to sales, we see a ratio of 1.24. The receivables turnover for the company is 16.27for trailing twelve months and the total asset turnover is 0.67. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.65.
Conclusion
In a nutshell, CureVac N.V (CVAC) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
